Processing

Please wait...

Settings

Settings

1. WO1996003125 - CARBON MONOXIDE DEPENDENT GUANYLYL CYCLASE MODIFIERS

Publication Number WO/1996/003125
Publication Date 08.02.1996
International Application No. PCT/US1995/010008
International Filing Date 25.07.1995
Chapter 2 Demand Filed 21.02.1996
IPC
A61K 31/52 2006.01
AHUMAN NECESSITIES
61MEDICAL OR VETERINARY SCIENCE; HYGIENE
KPREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
31Medicinal preparations containing organic active ingredients
33Heterocyclic compounds
395having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
495having six-membered rings with two nitrogen atoms as the only ring hetero atoms, e.g. piperazine
505Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
519ortho- or peri-condensed with heterocyclic rings
52Purines, e.g. adenine
CPC
A61K 31/52
AHUMAN NECESSITIES
61MEDICAL OR VETERINARY SCIENCE; HYGIENE
KPREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
31Medicinal preparations containing organic active ingredients
33Heterocyclic compounds
395having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
495having six-membered rings with two ; or more; nitrogen atoms as the only ring heteroatoms, e.g. piperazine ; or tetrazines
505Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
519ortho- or peri-condensed with heterocyclic rings
52Purines, e.g. adenine
A61K 31/522
AHUMAN NECESSITIES
61MEDICAL OR VETERINARY SCIENCE; HYGIENE
KPREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
31Medicinal preparations containing organic active ingredients
33Heterocyclic compounds
395having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
495having six-membered rings with two ; or more; nitrogen atoms as the only ring heteroatoms, e.g. piperazine ; or tetrazines
505Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
519ortho- or peri-condensed with heterocyclic rings
52Purines, e.g. adenine
522having oxo groups directly attached to the heterocyclic ring, e.g. hypoxanthine, guanine, acyclovir
A61K 31/7076
AHUMAN NECESSITIES
61MEDICAL OR VETERINARY SCIENCE; HYGIENE
KPREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
31Medicinal preparations containing organic active ingredients
70Carbohydrates; Sugars; Derivatives thereof
7042Compounds having saccharide radicals and heterocyclic rings
7052having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides
706containing six-membered rings with nitrogen as a ring hetero atom
7064containing condensed or non-condensed pyrimidines
7076containing purines, e.g. adenosine, adenylic acid
A61K 31/708
AHUMAN NECESSITIES
61MEDICAL OR VETERINARY SCIENCE; HYGIENE
KPREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
31Medicinal preparations containing organic active ingredients
70Carbohydrates; Sugars; Derivatives thereof
7042Compounds having saccharide radicals and heterocyclic rings
7052having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides
706containing six-membered rings with nitrogen as a ring hetero atom
7064containing condensed or non-condensed pyrimidines
7076containing purines, e.g. adenosine, adenylic acid
708having oxo groups directly attached to the purine ring system, e.g. guanosine, guanylic acid
Applicants
  • GLASKY, Alvin, J. [US/US]; US
  • RATHBONE, Michel [CA/CA]; CA
Inventors
  • GLASKY, Alvin, J.; US
  • RATHBONE, Michel; CA
Agents
  • MACLEAN, Kurt, A. ; Poms, Smith, Lande & Rose Suite 3800 2029 Century Park East Los Angeles, CA 90067, US
Priority Data
08/280,71925.07.1994US
08/488,97608.06.1995US
08/492,92920.07.1995US
Publication Language English (EN)
Filing Language English (EN)
Designated States
Title
(EN) CARBON MONOXIDE DEPENDENT GUANYLYL CYCLASE MODIFIERS
(FR) MODIFICATEURS DU GUANYLYLE DEPENDANTS DU MONOXYDE DE CARBONE
Abstract
(EN)
Disclosed herein are methods and associated compositions and medicaments directed generally to the control of cellular and neural activity and for selectively and controllably inducing the $i(in vivo) genetic expression of one or more naturally occurring genetically encoded molecules in mammals. More particularly, the present invention selectively activates or derepresses genes encoding for specific naturally occurring molecules such as proteins or neurotrophic factors and induces the endogenous production of such naturally occurring compounds through the administration of carbon monoxide dependent guanylyl cyclase modulating purine derivatives. The methods of the present invention may be used to affect a variety of cellular and neurological functions and activities and to therapeutically or prophylactically treat a wide variety of neurodegenerative, neurological, cellular, and physiological disorders.
(FR)
L'invention concerne des procédés ainsi que des compositions et des médicaments associés utilisés pour la régulation de l'activité cellulaire et neurale, et permettant d'induire, de manière sélective et modulable, l'expression génétique in vivo d'une ou plusieurs molécules génétiquement codées, d'origine naturelle, chez les mammifères. Plus particulièrement, la présente invention permet d'activer ou de déréprimer, de manière sélective, des gènes codant pour les molécules spécifiques d'origine naturelle, telles que les protéines ou des facteurs neurotrophiques, et d'induire la production endogène de ces composés d'origine naturelle par l'administration de dérivés de purine modulant le guanylyle cyclase dépendant du monoxyde de carbone. Les procédés selon la présente invention peuvent être utilisés pour modifier une variété de fonctions et d'activités cellulaires et neurologiques et pour traiter de manière thérapeutique ou prophylactique une grande variété de troubles neurodégénératifs, neurologiques, cellulaires et physiologiques.
Also published as
CZPV1996-3802
FI970302
KR1019970700597
NO19970312
NZ291592
Latest bibliographic data on file with the International Bureau